PEARL: 12-Month Clinical Follow-Up and First Long-Term Outcome
ArThec has completed the 12-month clinical follow-up of the first patient treated with its PEARL technology. This milestone provides the first long-term clinical outcome from the ongoing development of a biological approach to cartilage restoration based on autologous tissue.
The development of PEARL builds on research and engineering efforts aimed at restoring joint function using cartilage tissue derived from the patient’s own biological material. The transition from preclinical development to clinical application requires systematic evaluation of safety, feasibility, and clinical outcomes.
Clinical Course of the First Patient
The first patient treated with PEARL was a young woman who sustained a severe knee injury resulting in substantial pain and functional limitations. Before treatment, she experienced significant joint pain, restricted knee flexion, and required crutches and a rigid orthosis for mobility.
The patient underwent PEARL treatment under a hospital exemption program rather than conventional microfracture surgery or a membrane-based implant. The procedure involved transplantation of autologous hyaline cartilage tissue generated from a small sample of the patient’s own cartilage.
Clinical improvement was observed following implantation, with functional recovery occurring before the 12-month assessment. During follow-up, the patient regained knee mobility, returned to physical activity, and resumed daily activities that had previously been limited by the injury.
At the 12-month evaluation, the improvements observed earlier in the recovery period were maintained. The patient met the predefined criteria for a complete response and achieved the highest scores on the applicable clinical assessment scales.
12-Month Clinical Findings
The 12-month follow-up demonstrated sustained clinical improvement following PEARL treatment. The patient experienced a marked reduction in pain, with no pain reported at the 12-month assessment, and maintained her return to physical activity and normal daily activities throughout the follow-up period. The treatment used an autologous tissue-based approach, with cartilage tissue generated from the patient’s own biological material and without the use of synthetic scaffolds or foreign biomaterials as part of the cartilage graft.
These findings illustrate the clinical course and 12-month outcome of one patient treated with PEARL. Clinical outcomes from additional treated patients are being evaluated as part of the ongoing clinical development program and will contribute to the growing body of evidence on the safety, performance, and clinical potential of the PEARL approach.
Next Steps in Clinical Development
The completion of the first 12-month follow-up represents an important step in the clinical development of PEARL. Further evaluation is required to determine the reproducibility, safety, and clinical effectiveness of the approach across a larger and more diverse patient population.
The next stages of development include completing follow-up of additional patients treated under the hospital exemption program and generating further clinical evidence through a larger, multicenter study in Europe.
The objective of the clinical development program is to evaluate PEARL across broader patient populations and different clinical characteristics, while continuing to assess long-term clinical outcomes. The resulting evidence will inform subsequent stages of clinical development, including a planned Phase 3 clinical study.
PEARL is being developed as a biological approach to cartilage restoration, with the clinical program focused on establishing its safety, clinical performance, and potential role in the treatment of damaged joint cartilage.
